One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

Lecanemab, from Biogen and Japanese partner Eisai Co., is sold under the brand name Leqembi, and donanemab from Eli Lilly is branded as Kisunla. Both drugs work by reducing the brain amyloid ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

Lecanemab, from Biogen and Japanese partner Eisai Co., is sold under the brand name Leqembi, and donanemab from Eli Lilly is branded as Kisunla. Both drugs work by reducing the brain amyloid ...